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Ovarian cancer remains the most common cause of death
from gynaecological malignancy despite significant
improvement in both response rates and survival since the
introduction of cis-platin (Richardson et al., 1985). This
reflects the limitations of currently available chemo-
therapeutic combinations to eradicate ovarian cancer, and
indicates a continuing need to evaluate new drugs in this
disease.
Mitozolomide (NSC-353451; CCRG 81010; M&B 39565)
is a novel agent with structural similarities to the chloroethyl
nitrosoureas. It was synthesized as part of a programme to
evaluate the antitumour properties of small molecules
characterised by NNN linkages (Stevens et al., 1984). The
drug was highly active in preclinical studies (Hickman et al.,
1985) and during Phase I assessment, clinical response was
documented in two of ten patients with ovarian cancer
(Newlands et al., 1985). This Phase II study was initiated by
the Cancer Research Campaign Phase II Subcommittee to
evaluate further the activity of mitozolomide in epithelial
ovarian tumours.
Details of the 20 patients entered are shown in Table I:
Entry criteria included pretreatment WBC>3.0x 1091-1,
platelets > 100 x 1091-1 with normal renal and hepatic
function. No patient had been previously irradiated, and
response to prior chemotherapy was documented in 7 of 15
evaluable patients.
Patients received either 70mgm 2 or 90mgm-2
mitozolomide depending on the extent of prior therapy. This
was determined by the number of chemotherapy courses
rather than the number of different drugs (Table I), though
both age and performance status may have influenced the
decision.
Gelatin capsules were swallowed after a 4h fast, as
mitozolomide is degraded at alkaline pH (Stevens et al.,
1984). Retreatment was scheduled at intervals of 6 weeks,
haematological toxicity permitting. Full blood counts were
performed at 4 and 6 weeks post-treatment or more
frequently if clinically indicated. Patients experiencing nadir
Table I Characteristics of patients treated with mitozolomide
Dose ofmitozolomide
90mgm-2 (n=10) 70mgm-2 (n=10)
Age: median (range) 53 (38-64) 64 (52-72)
ECOG performance status 1.1 1.5
mean (range) (0-2) (0-2)
Number of prior cytotoxic 3 3
drugs: median (range) (1-5) (2-6)
Number of prior 8 14
chemotherapy courses (4-19) (6-20)
median (range)
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blood counts of WHO grade 2 thrombocytopenia and/or
grade 3 leucopenia received a 25% dose reduction on
subsequent courses; those with treatment-related morbidity
(infection or haemorrhage) were retreated at 50% of the
initial dose.
Tumour evaluation by clinical examination, supplemented
with abdominopelvic ultrasonography and CT scanning
where appropriate, was performed prior to each treatment
and response was defined by the standard UICC criteria.
Fifteen patients had abdominopelvic disease, 2 had liver and
3 extra-abdominal lymph nodes as the dominant tumour
sites.
Of the 20 patients treated, 11 received only one dose of
mitozolomide: Six received 2 and three received 3 doses. The
oral formulation (50, 60 or 70mg capsules) permitted
administration of 96-103% of the planned dosage (70 or
90mgm-2).
Ten patients (50%) experienced no gastrointestinal
toxicity. Five had nausea only and the others vomited 2-4h
after ingestion of mitozolomide; no gelatin capsules were
observed in the vomitus and drug absorption was assumed
to be complete.
The major toxicity was myelosuppression which occurred
4-6 weeks post-treatment (Table II). Two patients died
within 28 days of entry and are excluded as their nadir blood
counts were not measured; documentation was missing for a
third patient. Significant thrombocytopenia (WHO Grade 3
or 4) occurred following the first dose in 3 of 9 patients
receiving 90mgm-2 and 2 of 8 treated with 70mgm-2. Only
patients with grade 0, 1 or 2 toxicity were retreated and
significant thrombocytopenia occurred in 1 of 3 at each dose
level.
No deaths were directly attributable to myelosuppression,
though it may have been contributary in one instance. Four
patients had significant tumour related haemorrhage,
associated with thrombocytopenia; three required platelet
transfusion. No infective complications occurred.
No patient characteristic consistently predicted for severe
toxicity. One patient previously treated with carboplatin
(JM8, CBDCA) alone had grade 3 thrombocytopenia
following the first course, whereas 3 patients completing 3
courses of mitozolomide (with dose reduction in 1/3) had
received prior treatment with 2, 4 and 5 cytotoxic drugs
respectively. The patient with impaired renal function
Table II Myelosuppression resulting from mitozolomide therapy
Dose ofmitozolomide
70mgm-2 90mgm 2
1st Course n=8 n=9
Median nadir WBC (range) 5.6 (1.3-9.3) 3.3 (1.6-7.4)
Median nadir platelets (range) 141 (37-226) 75 (13-156)
2nd Course n=3 n=3
Median nadir WBC (range) 4.7 (1.4-7.4) 3.1 (0.6-7.3)
Median nadir platelets (range) 75 (30-140) 90 (5-200)
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(technically ineligible as pretreatment serum creatinine
212mmol 1- 1) received 3 doses at 90mgm-2 without
haematological toxicity. No patient had hyperbilirubinaemia,
but of the 3 patients with abnormal liver function due to
metastatic disease, 2 had no significant toxicity.
Six patients were not evaluable for response. Two died
within a month of treatment; one was considered an early
death from malignant disease, the definitive terminal event
for the other patient is unknown but she died at 13 days
without evident tumour progression or myelosuppression.
One patient had ascites but no evaluable disease, a second
received a single dose of mitozolomide and was not seen for
12 weeks by which time tumour progression was evident but
as reassessment was delayed, she was considered inevaluable.
Two patients had stable disease after the first course but, as
tumour related haemorrhage occurred, they were reluctant to
continue treatment.
No complete or partial response was seen in the 14
evaluable patients. Three patients with well defined
abdominopelvic masses had stable disease for 3+ months.
The other 11 patients had progressive disease as defined by a
>25% increase in tumour size (n =8), the appearance of
ascites (n=2) or new lesions (n=1). Six of these patients
died within 8 weeks of study entry.
Most patients in this study were extensively pretreated but
the lack of response was disappointing in view of
preliminary indications that mitozolomide was active in
advanced ovarian cancer, with two partial responses
documented after single i.v. doses of 115 and 153 mgm-2
(G. Blackledge, pers. comm.). It is possible that
mitozolomide has a steep dose/response curve and that the
doses used in this study were subtherapeutic. However, in
vitro, 15/16 primary cultures of human ovarian cancer cells
were resistant to higher concentrations of mitozolomide
(10pgml1) than have been achieved in vivo (7pgml- 1)
(Erba et al., 1986; Newlands et al., 1985) as 7 of these
tumours had not been exposed to prior chemotherapy, it is
possible that a majority of ovarian carcinomas are inherently
mitozolomide resistant.
Despite a reduction in the recommended Phase II dose
from 15 mggm-2 (Newlands et al., 1985) to 90mgm-2, 2 of
9 patients experienced grade 4 thrombocytopenia. Plasma
concentrations of mitozolomide were not measured in these
patients and it is possible that there is significant variation in
pharmacokinetic profiles between patients as myelo-
suppression, though partly dose related, was otherwise
unpredictable. Available data indicate that absorption of the
oral formulation is complete (Newlands et al., 1985) but a
correlation has not yet been established between the extent
of myelotoxicity and peak plasma levels or AUC.
In summary, mitozolomide appears to have no useful
activity in patients with extensively pretreated epithelial
ovarian cancer. The unpredictable myelosuppression is likely
to preclude further evaluation of this drug in a more
favourable patient population.
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